Published in Nicotine Tob Res on June 01, 2006
The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. Tob Control (2009) 3.10
Use of tobacco cessation treatments among young adult smokers: 2005 National Health Interview Survey. Am J Public Health (2007) 2.01
Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction (2012) 1.32
Natural history of attempts to stop smoking. Nicotine Tob Res (2014) 1.20
Motivating the unmotivated for health behavior change: a randomized trial of cessation induction for smokers. Clin Trials (2010) 1.15
Predictors of cessation pharmacotherapy use among black and non-Hispanic white smokers. Nicotine Tob Res (2011) 1.10
Expectancies for cigarettes, e-cigarettes, and nicotine replacement therapies among e-cigarette users (aka vapers). Nicotine Tob Res (2014) 1.09
Misperceptions of nicotine replacement therapy within racially and ethnically diverse smokers. J Natl Med Assoc (2012) 1.08
How people think about the chemicals in cigarette smoke: a systematic review. J Behav Med (2017) 1.04
Educating smokers about their cigarettes and nicotine medications. Health Educ Res (2010) 0.94
Beliefs and attitudes about bupropion: implications for medication adherence and smoking cessation treatment. Psychol Addict Behav (2009) 0.90
Yoga as a complementary treatment for smoking cessation in women. J Womens Health (Larchmt) (2011) 0.89
Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence. BMC Public Health (2010) 0.88
Effects of instructions on responses to the nicotine patch: a laboratory study. Psychopharmacology (Berl) (2007) 0.88
Why do smokers try to quit without medication or counselling? A qualitative study with ex-smokers. BMJ Open (2015) 0.85
Why Don't Smokers Want Help to Quit? A Qualitative Study of Smokers' Attitudes towards Assisted vs. Unassisted Quitting. Int J Environ Res Public Health (2015) 0.83
Changing low income smokers' beliefs about tobacco dependence treatment. Subst Use Misuse (2014) 0.81
A mechanistic test of nicotine replacement therapy sampling for smoking cessation induction. Psychol Addict Behav (2014) 0.81
The role of nicotine replacement therapy in early quitting success. Nicotine Tob Res (2009) 0.78
Smokers' Treatment Expectancies Predict Smoking Cessation Success. J Smok Cessat (2014) 0.77
African American smokers' intention to use pharmacotherapy for cessation. Am J Health Behav (2012) 0.77
Group hypnotherapy versus group relaxation for smoking cessation: an RCT study protocol. BMC Public Health (2012) 0.77
Group hypnosis vs. relaxation for smoking cessation in adults: a cluster-randomised controlled trial. BMC Public Health (2013) 0.76
Knowledge about nicotine among HIV-positive smokers: Implications for tobacco regulatory science policy. Addict Behav (2016) 0.75
U.S. adults' addiction and harm beliefs about nicotine and low nicotine cigarettes. Prev Med (2016) 0.75
Randomized Trial of Reduced-Nicotine Standards for Cigarettes. N Engl J Med (2015) 3.63
Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst (2004) 1.99
Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem Res Toxicol (2009) 1.89
Racial/Ethnic disparities in the use of nicotine replacement therapy and quit ratios in lifetime smokers ages 25 to 44 years. Cancer Epidemiol Biomarkers Prev (2008) 1.87
Reconciling human smoking behavior and machine smoking patterns: implications for understanding smoking behavior and the impact on laboratory studies. Cancer Epidemiol Biomarkers Prev (2009) 1.82
Similar uptake of lung carcinogens by smokers of regular, light, and ultralight cigarettes. Cancer Epidemiol Biomarkers Prev (2005) 1.77
Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. Cancer Epidemiol Biomarkers Prev (2005) 1.76
Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomarkers Prev (2009) 1.74
Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. Cancer Epidemiol Biomarkers Prev (2007) 1.66
Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend (2008) 1.59
Views on smoking cessation methods in ethnic minority communities: a qualitative investigation. Prev Med (2006) 1.57
Quantitation of acrolein-derived (3-hydroxypropyl)mercapturic acid in human urine by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: effects of cigarette smoking. Chem Res Toxicol (2007) 1.49
Physical activity and alcohol use disorders. Am J Drug Alcohol Abuse (2012) 1.48
Smoker characteristics and smoking-cessation milestones. Am J Prev Med (2011) 1.47
Race differences in nicotine dependence in the Collaborative Genetic study of Nicotine Dependence (COGEND). Nicotine Tob Res (2008) 1.42
Effects of progesterone treatment on smoked cocaine response in women. Pharmacol Biochem Behav (2002) 1.34
Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. Tob Control (2007) 1.30
Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. Nicotine Tob Res (2009) 1.29
Effective tobacco dependence treatment. JAMA (2002) 1.25
Personality, psychiatric disorders, and smoking in middle-aged adults. Nicotine Tob Res (2009) 1.25
Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example. Cancer Epidemiol Biomarkers Prev (2009) 1.24
Applying the tripartite model of anxiety and depression to cigarette smoking: an integrative review. Nicotine Tob Res (2010) 1.24
Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine. Nicotine Tob Res (2007) 1.23
Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype. J Pharmacol Exp Ther (2009) 1.22
A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers. Cancer Epidemiol Biomarkers Prev (2004) 1.21
The effect of five smoking cessation pharmacotherapies on smoking cessation milestones. J Consult Clin Psychol (2011) 1.20
Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol (2005) 1.19
Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. Cancer Epidemiol Biomarkers Prev (2008) 1.18
Perceived risk of harm from cigarettes or smokeless tobacco among U.S. high school seniors. Nicotine Tob Res (2007) 1.18
Quantitation of an acetaldehyde adduct in human leukocyte DNA and the effect of smoking cessation. Chem Res Toxicol (2007) 1.16
Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study. Cancer Epidemiol Biomarkers Prev (2010) 1.15
Comparison of polymorphisms in genes involved in polycyclic aromatic hydrocarbon metabolism with urinary phenanthrene metabolite ratios in smokers. Cancer Epidemiol Biomarkers Prev (2006) 1.15
Assessing consumer responses to potential reduced-exposure tobacco products: a review of tobacco industry and independent research methods. Cancer Epidemiol Biomarkers Prev (2009) 1.13
The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev (2013) 1.13
Monitoring tobacco-specific N-nitrosamines and nicotine in novel Marlboro and Camel smokeless tobacco products: findings from Round 1 of the New Product Watch. Nicotine Tob Res (2011) 1.12
Positive reactions to tobacco predict relapse after cessation. J Abnorm Psychol (2011) 1.11
Effect of differing levels of tobacco-specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers. Cancer Epidemiol Biomarkers Prev (2010) 1.11
The association of a tobacco-specific biomarker and cigarette consumption and its dependence on host characteristics. Cancer Epidemiol Biomarkers Prev (2007) 1.10
Smoking reduction fails to improve clinical and biological markers of cardiac disease: a randomized controlled trial. Nicotine Tob Res (2008) 1.09
Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use. Cancer Res (2002) 1.09
Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nat Rev Cancer (2009) 1.09
Conference on abuse liability and appeal of tobacco products: conclusions and recommendations. Drug Alcohol Depend (2011) 1.09
Anhedonia and anxiety sensitivity: prospective relationships to nicotine withdrawal symptoms during smoking cessation. J Stud Alcohol Drugs (2013) 1.08
Efficacy of nicotine patch in smokers with a history of alcoholism. Alcohol Clin Exp Res (2003) 1.07
Sensation seeking as a predictor of treatment compliance and smoking cessation treatment outcomes in heavy social drinkers. Pharmacol Biochem Behav (2009) 1.04
Sex differences in negative affect and lapse behavior during acute tobacco abstinence: a laboratory study. Exp Clin Psychopharmacol (2013) 1.04
Extensive metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers. Cancer Epidemiol Biomarkers Prev (2008) 1.02
Beliefs and experiences regarding smoking cessation among American Indians. Nicotine Tob Res (2007) 1.01
Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. Carcinogenesis (2012) 1.01
Flavored and nonflavored smokeless tobacco products: rate, pattern of use, and effects. Nicotine Tob Res (2012) 1.01
CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. Pharmacogenet Genomics (2012) 1.00
Anxiety sensitivity as a predictor of acute subjective effects of smoking. Nicotine Tob Res (2012) 0.99
Carcinogenic tobacco-specific N-nitrosamines in US cigarettes: three decades of remarkable neglect by the tobacco industry. Tob Control (2011) 0.99
Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug Alcohol Depend (2003) 0.98
Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. Psychopharmacology (Berl) (2007) 0.98
Time-varying smoking abstinence predicts lower depressive symptoms following smoking cessation treatment. Nicotine Tob Res (2010) 0.97
Tobacco smoke exposure in nonsmoking hospitality workers before and after a state smoking ban. Cancer Epidemiol Biomarkers Prev (2010) 0.96
Where is the pleasure in that? Low hedonic capacity predicts smoking onset and escalation. Nicotine Tob Res (2012) 0.96
A testable prognostic model of nicotine dependence. J Neurogenet (2009) 0.96
Test of measurement invariance of the FTND across demographic groups: assessment, effect size, and prediction of cessation. Drug Alcohol Depend (2007) 0.96
Race and nicotine replacement treatment outcomes among low-income smokers. Am J Prev Med (2008) 0.96
Relationships of personality and psychiatric disorders to multiple domains of smoking motives and dependence in middle-aged adults. Nicotine Tob Res (2010) 0.96
The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers. Biomarkers (2011) 0.95
Patterns of self-selected smoking cessation attempts and relapse by menstrual phase. Addict Behav (2009) 0.95
Hostility, cigarette smoking, and responses to a lab-based social stressor. Exp Clin Psychopharmacol (2009) 0.95
Effectiveness of over-the-counter nicotine replacement therapy. JAMA (2002) 0.95
Effects of reduced cigarette smoking on levels of 1-hydroxypyrene in urine. Cancer Epidemiol Biomarkers Prev (2004) 0.94
Age and gender as moderators of the relationship between physical activity and alcohol use. Addict Behav (2011) 0.93
Nicotine withdrawal and craving in adolescents: effects of sex and hormonal contraceptive use. Addict Behav (2009) 0.91
Sex differences in stimulus expectancy and pharmacologic effects of a moderate dose of alcohol on smoking lapse risk in a laboratory analogue study. Psychopharmacology (Berl) (2012) 0.91
UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption. Cancer Epidemiol Biomarkers Prev (2010) 0.91
Marijuana use and tobacco smoking cessation among heavy alcohol drinkers. Drug Alcohol Depend (2011) 0.90
Detecting longitudinal patterns of daily smoking following drastic cigarette reduction. Addict Behav (2007) 0.90
Metabolism of [D10]phenanthrene to tetraols in smokers for potential lung cancer susceptibility assessment: comparison of oral and inhalation routes of administration. J Pharmacol Exp Ther (2011) 0.90
Metabolism of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone to its biomarker total NNAL in smokeless tobacco users. Cancer Epidemiol Biomarkers Prev (2008) 0.90
Abstinence-related expectancies predict smoking withdrawal effects: implications for possible causal mechanisms. Psychopharmacology (Berl) (2013) 0.89
Major tobacco companies have technology to reduce carcinogen levels but do not apply it to popular smokeless tobacco products. Tob Control (2010) 0.89
Smokeless tobacco reduction with the nicotine lozenge and behavioral intervention. Nicotine Tob Res (2010) 0.88
Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers. Nicotine Tob Res (2003) 0.88
Associations between attention deficit hyperactivity disorder symptom domains and DSM-IV lifetime substance dependence. Am J Addict (2013) 0.88
Urinary metabolites of a tobacco-specific lung carcinogen in nonsmoking hospitality workers. Cancer Epidemiol Biomarkers Prev (2005) 0.88
Smoking abstinence and reinstatement effects in adolescent cigarette smokers. Nicotine Tob Res (2009) 0.88
Associations between posttraumatic stress disorder symptom clusters and cigarette smoking. Psychol Addict Behav (2011) 0.88
Smokeless tobacco topography and toxin exposure. Nicotine Tob Res (2005) 0.87
Hostility and smoking cessation treatment outcome in heavy social drinkers. Psychol Addict Behav (2009) 0.87
Kinetics of DNA adduct formation in the oral cavity after drinking alcohol. Cancer Epidemiol Biomarkers Prev (2012) 0.87
Exposure to nicotine and carcinogens among Southwestern Alaskan Native cigarette smokers and smokeless tobacco users. Cancer Epidemiol Biomarkers Prev (2012) 0.87
Diagnosing alcohol abuse in alcohol dependent individuals: diagnostic and clinical implications. Addict Behav (2009) 0.87
Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation. Nicotine Tob Res (2012) 0.87
Dysphoria and smoking among treatment seeking smokers: the role of smoking-related inflexibility/avoidance. Am J Drug Alcohol Abuse (2014) 0.87
Cigarette smoking reduction and changes in nicotine dependence. Nicotine Tob Res (2011) 0.87
Transdisciplinary science applied to the evaluation of treatments for tobacco use. Nicotine Tob Res (2003) 0.86
Multiple distinct CHRNB3-CHRNA6 variants are genetic risk factors for nicotine dependence in African Americans and European Americans. Addiction (2014) 0.86
Tobacco use among southwestern Alaska Native people. Nicotine Tob Res (2012) 0.86
Associations between depressive symptom dimensions and smoking dependence motives. Eval Health Prof (2010) 0.86
The effect of individual cocaine withdrawal symptoms on outcomes in cocaine users. Addict Behav (2004) 0.86
Effect of bupropion on physiological measures of stress in smokers during nicotine withdrawal. Pharmacol Biochem Behav (2006) 0.86
Urinary 3,3'-diindolylmethane: a biomarker of glucobrassicin exposure and indole-3-carbinol uptake in humans. Cancer Epidemiol Biomarkers Prev (2013) 0.85
Epidemiology, determinants, and consequences of cigarette smoking in African American women: an integrative review. Addict Behav (2009) 0.85
Relationships between trait urgency, smoking reinforcement expectancies, and nicotine dependence. J Addict Dis (2014) 0.84